Abcam, ab264505, Human FXR1 knockout HeLa cell lysate

Size: 1Kit
FXR1 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-FXR1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The FXR1 protein also known as Fragile X Mental Retardation Syndrome-related Protein 1 weighs approximately 80 kDa and is expressed in various tissues including the brain heart and the skeletal muscles. It belongs to the family of RNA-binding proteins that also includes FMR1 and FXR2. Mechanically FXR1 interacts with mRNA participating in the regulation of its stability and translation. This regulation allows cells to control protein synthesis important for many cellular processes.
Biological function summary
FXR1 is involved in the post-transcriptional regulation of gene expression important for normal cell function and development. It forms a complex with FMRP playing an important role in the transport and translation of specific subsets of mRNAs in neurons. This interaction suggests it contributes significantly to the synaptic plasticity mechanisms influencing learning and memory. Moreover FXR1 also seems to have functions in cell proliferation and muscle differentiation.
Pathways
FXR1 participates in key regulatory pathways of protein synthesis and neuronal communication. It is significant in the mTOR signaling pathway where it potentially interacts with other proteins like FXR2 and FMR1 to modulate translational control. FXR1's involvement in this pathway suggests a role in cellular growth and neuron-specific processes affecting how cells respond to various growth signals by altering protein synthesis rates.
FXR1 links to psychiatric disorders including schizophrenia and bipolar disorder. Gene dysregulation in FXR1 may disrupt normal synaptic functioning contributing to the pathophysiology of these conditions. In muscular dystrophies altered FXR1 expression has been reported associating it with muscle tissue protein dynamics along with FMR1 influencing muscle regeneration and repair mechanisms. These associations highlight FXR1’s potential as a therapeutic target in neurodevelopmental and muscle-related diseases.